MCRB News and Press, Seres Therapeutics Inc. From 03/07/23

– SER-109 Biologics License Application (BLA) under review with U.S. Food and Drug Administration (FDA) with target action date of April 26, 2023 under Prescription Drug User Fee Act (PDUFA) – – Anticipate SER-109 commercial launch soon after potential FDA approva...

2023-03-06 11:14:22 ET Seres Therapeutics ( NASDAQ: MCRB ) is scheduled to announce FY earnings results on Tuesday, March 7th, before market open. The consensus EPS Estimate is -$2.12 (-194.4% Y/Y) and the consensus Revenue Estimate is $13.75M (-90.5% Y/Y). For furth...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update. ...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:...

– Clinical data, showing that 91.3% of subjects remained free of C. difficile infection recurrence at 8 weeks, support and extend previous Phase 3 study results – – SER-109 associated with rapid and steady improvement in HRQOL, an important patient-related outcome, co...

Summary It's a challenging time for biotechs needing cash. Sana Biotechnology is such a company from the stable of Boston-based Flagship Pioneering. Sana was launched to pioneer a particular aspect of DNA-based therapies. This is new and revolutionary and likely to take time to matu...

– Company anticipates reporting initial SER-155 safety and pharmacological data from study Cohort 1 in the coming months – Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that enrollment in Cohort 2 in its SER-15...

Summary Today, we take a look at microbiome therapeutic developer Seres Therapeutics, Inc. Seres Therapeutics appears headed to its first FDA approval and has a strategic partnership with Nestlé S.A. around this endeavor. Will the FDA greenlight trigger a rally in the shares?&#...

Summary April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff. FNCH is a casualty of setbacks at the beginning of the new medical ...

Summary Novartis is one of the world’s most successful pharma companies and it is undergoing a major change to become a pure-play innovative medicines company. Part of this also involves Novartis pursuing a “US-First mindset”, which might prefer money at the expense...